Table 3.

HPV vaccination among adolescent females, 2008–2010 National Immunization Survey-Teen

HPV vaccine initiationHPV vaccine completionHPV vaccine follow-througha
Weighted%Bivariate OR (95% CI)Multivariate ORb (95% CI)Weighted%Bivariate OR (95% CI)Multivariate ORb (95% CI)Weighted%Bivariate OR (95% CI)Multivariate ORb (95% CI)
Appalachia40.80.89 (0.78–1.02)0.92 (0.79–1.07)27.71.13 (0.97–1.31)1.12 (0.95–1.32)67.81.53 (1.24–1.88)**1.36 (1.07–1.72)*
Non-Appalachia43.6Ref.Ref.25.3Ref.Ref.58.1Ref.Ref.

NOTE: Because of missing data, final models included n = 25,106 for HPV vaccine initiation and completion and 11,140 for HPV vaccine follow-through.

Abbreviations: Ref., referent group; HPV, human papillomavirus; OR, odds ratio; CI, confidence interval.

*, P < 0.05; **, P < 0.001.

  • aHPV vaccine completion among only those adolescent females who initiated the HPV vaccine regimen.

  • bAdjusted for year of data collection, daughter's age, daughter's race/ethnicity, whether daughters had visited a healthcare provider in the last year, daughter's healthcare coverage, mother's age, mother's education, mother's marital status, parent's HPV awareness, parent's HPV vaccine awareness, whether parent had ever received a healthcare provider recommendation to get daughter HPV vaccine, poverty status, and urbanicity.